Among adults under 50, colorectal cancer is now the leading cause of cancer death in men and the second in women. It arrives earlier, hits harder, and, for the vast majority of patients, has resisted the immunotherapy revolution that turned cancers like melanoma from death sentences into survivable diagnoses.

The reason is biological. About 85 percent of colon cancers are microsatellite stable, or MSS. These are “cold” tumors that hide from the immune system, and they have shrugged off every checkpoint inhibitor thrown at them. No new class of therapy has been approved for this population in more than two decades.

Garo Armen believes he has the drug that changes that, and he is not alone. With more than 1,000 patients treated and striking results from two mid-stage trials now published in peer-reviewed journals and presented at major conferences, researchers, physicians, and patients are lining up behind a medicine that could break one of oncology's longest stalemates.

Today Armen has the science and the funding he believes will carry the drug across the finish line. Yet only months ago his company was fighting for its life. How does that happen?

The answer runs through the most precarious stretch of a long career, a story of scientific conviction, regulatory setbacks, and endurance against odds that turned back every previous attempt. What is different now is that, for the first time in a generation, the balance in colorectal cancer may finally be shifting.

An Armenian Messenger Boy in New York

Armen's war with cancer is personal, and it is old. Born in Istanbul to an Armenian family in 1953, he arrived in New York in 1970 with almost nothing and took his first job as a messenger boy at two dollars an hour. In 1972 his mother joined him. She was already gravely ill, cancerous tumors visible on her head, and after a hard struggle she died later that year in the one-room Brooklyn apartment they shared. Her son was nineteen.

He has spent the fifty years since closing the distance to that loss. First through science: a PhD in physical chemistry and a research fellowship at Brookhaven National Laboratory. Then through Wall Street: an analyst's desk at E.F. Hutton, pharmaceutical research leadership at Dean Witter, his own healthcare investment partnership, and by 1993 the architecture of the Immunex and Lederle oncology deal, one of the most closely watched transactions in the industry at the time.

Then, in 1994, a biochemist named Pramod Srivastava came to him with an idea for training a patient's own immune system against their own tumor. Armen did not advise on the company. He co-founded it, and he never left.

Thirty Years Too Early

Antigenics, today Agenus, has pursued one mission ever since: turning the immune system into a weapon against cancer. For most of those thirty years, that made the company early. Painfully early.

Its first flagship, the personalized cancer vaccine Oncophage, became the first therapeutic cancer vaccine approved anywhere in the world, in Russia in 2008. American approval never came; regulators demanded trials the company could not then afford. It became the pattern that would define Agenus for decades: science ahead of its time, colliding with a system built for what came before.

Yet the proof accumulated, sometimes where no one was looking. The company's QS-21 Stimulon adjuvant became a component of GSK's Shingrix, one of the most successful vaccines in the world. And when the accounting scandals of 2002 sent Elan Corporation into freefall, it was Armen the board asked to take the chairmanship. He led a multibillion-dollar turnaround while continuing to run Agenus, and while building a humanitarian legacy in rural Armenia through the Children of Armenia Fund.

The rescue résumé was complete. The cancer mission was not.

The Drug That Turns Cold Tumors Hot

That mission now rests on two antibodies. Botensilimab is engineered to ignite an immune response where conventional checkpoint inhibitors, the drugs that release the immune system's brakes, have failed. Balstilimab keeps that response burning. Together, they aim to do what no immunotherapy has done: turn cold tumors hot and bring the immuno-oncology revolution to the patients it left behind.

The combination has been tested in more than 1,000 patients across tumor types. But the data that changed everything came from two mid-stage studies, NEST and UNICORN, in which patients with MSS colorectal cancer received the treatment before surgery. Roughly 60 to 70 percent showed pathologic responses. About 30 percent had pathologic complete responses, meaning no detectable tumor remained. And at the time of this reporting, every patient treated in those studies remains disease-free.

In this cancer, in this population, nothing like it has been seen from any treatment.

Two Years on the Edge

Yet as the data strengthened, the company nearly died. Registrational trials cost hundreds of millions of dollars, and through two years of financial crisis the funding was simply not there. Agenus cut staff, sold assets, and watched its runway shrink to months. The old pattern seemed to be repeating: the science arriving before the world was ready to pay for it.

Then Armen made the kind of decision that defines his career. In mid-2026, the company shut down the Phase 3 trial in late-stage metastatic disease it had launched only three months earlier, to concentrate everything on the setting where tumors were disappearing: treating colon cancer before surgery, when the disease can still be eradicated.

It was a ruthless bet, made from a position of near-total weakness. The market answered it.

The Deal

In July 2026, Agenus announced an oversubscribed private placement of up to $340 million, with $85 million upfront and up to $255 million more on warrant exercise, led by Commodore Capital, with RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals as investors. The financing funds ROBBIN, a global registrational Phase 3 trial enrolling approximately 850 patients with high-risk Stage II and III MSS colon cancer, and, assuming full warrant exercise, the company's operations through 2031.

This was not a lifeline extended out of charity. It was specialist biotech investors, the most skeptical money in the world, validating the data, the strategy, and the man.

The Tipping Point

Thirty-two years after co-founding the company, Armen is closer than he has ever been. He expects ROBBIN to confirm what NEST and UNICORN showed. If it does, BOT/BAL would become the first immunotherapy to crack the largest, coldest population in colorectal cancer: tens of thousands of patients a year with a genuine shot at cure, in a disease that is stalking the young.

Every tipping point looks inevitable in hindsight and impossible the day before. From a Brooklyn apartment to Wall Street to the edge of insolvency and back, Armen has been leaning his full weight against this one. The drug is real. The money is in place. The trial is designed.

What remains is the hardest thing in biotech, and the only thing that has ever mattered to him: delivering.

‍